Skip to content

Study on Patients’ Willingness to Pay Published in an International Scientific Journal

AcuCort AB has announced that an article on a study regarding Swedish patients’ willingness to pay for Zeqmelit® will be published in the scientific journal Journal of Health Economics and Outcomes Research.

The scientific study presented in the article is titled Treatment preferences for acute allergic reactions – a discrete choice experiment in Sweden. The study investigates the willingness to pay for a corticosteroid oral film among Swedish individuals with acute allergic reactions. The premise is that corticosteroids are a common treatment for acute allergic reactions, and the oral film offers an alternative to corticosteroid tablets, which can be difficult to administer in an acute situation. The study results show a high willingness to pay among patients.

The study is part 2 of a larger survey study conducted in collaboration with IHE, the Institute for Health Economics. Part 1 focuses on treatment preferences among Swedish patients with acute allergic reactions and was published in April 2024 in the scientific peer-reviewed journal World Allergy Organization Journal.

“Part 1 of the study clarifies that there is a significant and clear patient need for a medication like Zeqmelit®. The article on part 2 will increase awareness that there is also a strong willingness to pay for Zeqmelit® among patients,” says Jonas Jönmark, CEO of AcuCort.

“It is a significant recognition for the treatment with Zeqmelit® that AcuCort’s study on the willingness to pay among allergy patients is featured in a well-respected scientific journal that reaches a large portion of our direct target audience. The timing is also perfect as the launch of Zeqmelit® is planned for this summer,” says Jonas Jönmark.

The article in the Journal of Health Economics and Outcomes Research is expected to be published in the summer of 2024.

For further information:
Jonas Jönmark, CEO AcuCort AB
Tel: +46 70 3655400

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit for more information.